Wagner scores 25 as the Magic shut down Nets late on the way to a 105-98 victory

ORLANDO, Fla. (AP) — Franz Wagner scored 25 points, Tristan da Silva added 22 points and nine rebounds and the Orlando Magic held Brooklyn scoreless over the final two-and-a-half minutes for a 105-98 victory over the Nets on Friday night.

The win was Orlando's second in NBA Cup Group play and dropped Brooklyn to 0-2.

Michael Porter Jr. had 24 points and 11 rebounds for the Nets, who led 98-94 after a basket by Nic Claxton with 2:37 remaining. But, Wagner hit two 3-pointers, da Silva made one and Brooklyn never scored again.

Desmond Bane scored nine of his 19 points in the fourth quarter for Orlando and Jalen Suggs finished with 14 points, seven rebounds and six assists.

Ziaire Williams had 15 points and a steal late in the fourth quarter — off Orlando's 19th turnover — that put the Nets up 96-92. Noah Clowney had 12 points before fouling out with 1:58 remaining.

Da Silva got his first start of the season in place of Paolo Banchero, who is out with a strained left groin.

The Nets had a 53-37 lead midway through the second quarter, helped by 3-pointers, 59% overall shooting and 10 Magic turnovers. Three-pointers by da Silva and Bane, and Goga Bitadze's block of an attempted dunk by Terrance Mann, turned the game around quickly. Orlando outscored the Nets 25-5 over the next eight minutes and led by as many as seven in the third quarter.

After making six of their first 11 3-point shots, the Nets made only four of 29 and lost for the 11th time in 12 games.

Nets: At Washington on Sunday.

Magic: At Houston on Sunday.

AP NBA: https://apnews.com/hub/nba

Orlando Magic guard Desmond Bane, left, has pass blocked by Brooklyn Nets guard Drake Powell (4) and team mate Nets center Nic Claxton, center, during the first half of an NBA Cup basketball game, Friday, Nov. 14, 2025, in Orlando, Fla. (AP Photo/Kevin Kolczynski)

Brooklyn Nets center Day'Ron Sharpe (20) shoots over Orlando Magic center Wendell Carter Jr. (34) during the first half of an NBA Cup basketball game Friday, Nov. 14, 2025, in Orlando, Fla. (AP Photo/Kevin Kolczynski)

Orlando Magic center Goga Bitadze (35) defends Brooklyn Nets center Nic Claxton (33) during the first half of an NBA Cup basketball game, Friday, Nov. 14, 2025, in Orlando, Fla. (AP Photo/Kevin Kolczynski)

Orlando Magic guard Jalen Suggs, right, and Magic forward Franz Wagner, center, stop Brooklyn Nets forward Ziaire Williams, left, lay-up during the first half of an NBA Cup basketball game, Friday, Nov. 14, 2025, in Orlando, Fla. (AP Photo/Kevin Kolczynski)

Orlando Magic guard Jett Howard, right, and Brooklyn Nets forward Ziaire Williams, left, go after a loose ball during the first half of an NBA Cup basketball game Friday, Nov. 14, 2025, in Orlando, Fla. (AP Photo/Kevin Kolczynski)

維也納--(BUSINESS WIRE)--十二月 8, 2025--

(美國商業資訊)-- AOP Health持續推進其在骨髓增生性腫瘤(一類特殊且罕見的血液腫瘤)領域的臨床研發計畫。這家專注於罕見疾病治療的公司，於2025年在美國佛羅里達州奧蘭多舉行的第67 屆美國血液學會(American Society of Hematology, ASH)年會上，發布了兩項科學研究成果，將為治療策略帶來新的見解。

本新聞稿包含多媒體資訊。完整新聞稿請見此： https://www.businesswire.com/news/home/20251207103807/zh-HK/

ROP-ET與BESREMI PASS

其中一項臨床研究ROP-ET，探討Ropeginterferon alfa-2b在 原發性血小板增多症 (ET)患者中的使用情況。ET是一種由於體內產生的血小板過多而引發的疾病。此試驗為一項前瞻性、多中心、單組第III期臨床研究，評估Ropeginterferon alfa-2b在無法接受現有細胞減量治療 1 的ET患者中的安全性與療效。

另一項研究為BESREMI-PASS研究，旨在觀察該藥物在 原發性紅血球增多症 (PV)患者日常臨床治療中的效果。PV是一種罕見的血液幹細胞癌症，起源於骨髓造血幹細胞，會導致紅血球、白血球及血小板長期異常增多。

致力於滿足尚未被滿足的醫療需求

上述兩項研究，皆為Ropeginterferon α-2b在協助慢性血癌患者治療方面提供了新的見解。

AOP Health執行長Martin Steinhart總結道： 「AOP Health創立的初衷，正是為了回應罕見疾病領域中尚未被滿足的患者需求。我們對研發的持續投入，正體現了這項承諾，並帶來了新的研究成果。我們很榮幸能在ASH年會上，與全球科學界分享這些發現。」

關於Ropeginterferon alfa-2b

Ropeginterferon alfa-2b為全球首個獲准用於治療真性紅血球增多症(MPN)的干擾素藥物。依據歐盟核准內容，該藥物可作為單一療法，用於治療未出現脾腫大症狀的成人真性紅血球增多症患者。

Ropeginterferon alfa-2b屬於長效單聚乙二醇化脯氨酸干擾素(ATC：L03AB15)。初始治療階段為每兩週給藥一次，待血液學指標穩定後，可延長至每四週給藥一次。藥品採用預充式注射筆設計，供患者進行皮下注射使用。

關於AOP Health

AOP Orphan Pharmaceuticals GmbH (「AOP Health」)為一家跨國企業集團，根植於奧地利，集團總部亦設於此。自1996年成立以來，AOP Health Group持續致力於開發創新治療方案，以回應尚未被滿足的醫療需求，重點聚焦於罕見疾病與重症醫學領域。作為整合式治療方案的國際先驅，AOP Health Group透過子公司、代表處及強大的合作夥伴網路，在全球多地開展業務。秉持「需求、科學、信任」的核心理念，AOP Health Group強調對科研的長期承諾，並重視與醫療專業人士及病友組織的合作，確保關鍵利害關係人的需求能貫穿於公司各項行動之中。(aop-health.com)

1 Kiladjian JJ、Marin FF、Al-Ali HK等。ROP-ET：一項評估Ropeginterferon α-2b在治療選擇有限之原發性血小板增多症患者中有效性與安全性的前瞻性第III期臨床試驗。《血液學年鑑》，2024年3月4日：1–2。

需求、科學、信任。(Needs. Science. Trust.)
AOP Orphan Pharmaceuticals GmbH
AOP Health Group成員

免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。

請前往 businesswire.com 瀏覽源版本:https://www.businesswire.com/news/home/20251207103807/zh-HK/

CONTACT: 深入咨詢

DI Isolde Fally

Isolde.Fally@aop-health.com

+43-676-500 4048

KEYWORD: AUSTRIA EUROPE UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY GENERAL HEALTH HEALTH CLINICAL TRIALS

SOURCE: AOP Health

Copyright Business Wire 2025.

PUB: 12/08/2025 12:14 AM/DISC: 12/08/2025 12:15 AM

http://www.businesswire.com/news/home/20251207103807/zh

AOP Health執行長Martin Steinhart博士；圖片來源：AOP Health/Studio Koekart